Printer Friendly

XOMA REPORTS 1992 THIRD QUARTER FINANCIAL RESULTS

 XOMA REPORTS 1992 THIRD QUARTER FINANCIAL RESULTS
 BERKELEY, Calif., Nov. 5 /PRNewswire/ -- XOMA Corp.


(NASDAQ-NMS: XOMA) today reported its financial results for the 1992 third quarter.
 For the quarter ended Sept. 30, 1992, XOMA had revenues of $0.7 million and a net loss of $19.0 million (89 cents per share). As previously reported, the loss reflects a one-time charge of $10.0 million for personnel expenses associated with a corporate restructuring, idle production capacity costs, and the establishment of a reserve for inventory. Without the one-time charge, the company's third quarter 1992 loss would have been $9.0 million (42 cents per share).
 In the 1991 third quarter, XOMA recorded revenues of $4.3 million and a net loss of $9.0 million (42 cents per share). The decline in revenues in 1992 compared to the 1991 period was due to lower research and development fees from and product sales to Pfizer Inc., XOMA's marketing partner for its E5 anti-endotoxin monoclonal antibody, and to the completion of funding from the Ortho Biotech division of Johnson & Johnson related to development of the company's CD5 Plus product for certain immune system disorders.
 At Sept. 30, 1992, XOMA had total assets of $118.9 million, including cash and short-term investments of $92.7 million, and stockholders' equity of $97.0 million.
 XOMA is a leading biotechnology company in the development of proprietary products for the treatment of infectious diseases and immune system disorders.
 XOMA CORP.
 Balance Sheet Data Sept. 30 Dec. 31
 (In thousands) 1992 1991
 Current assets $101,936 $139,495
 Total assets 118,904 154,289
 Long-term debt 1,172 1,503
 Stockholders' equity 97,029 134,456
 Statement of Three Months Ended Nine Months Ended
 Operations Data Sept. 30 Sept. 30
 (In thousands except 1992 1991 1992 1991
 per share data)
 Total revenues $ 720 $ 4,253 $ 4,530 $14,306
 Total operating costs
 & expenses(A) 20,920 15,852 43,843 42,702
 Other income 1,215 2,561 4,376 4,641
 Litigation settlement 0 0 (3,250) 0
 Net loss (18,985) (9,038) (38,187) (23,755)
 Net loss per share (0.89) (0.42) (1.78) (1.27)
 Weighted average common
 shares outstanding 21,451 21,405 21,442 18,719
 (A) 1992 figures include $10.0 million one-time charge.
 Shares outstanding at Sept. 30, 1992: 21,453,848
 -0- 11/5/92
 /CONTACT: Carol DeGuzman of XOMA, 510-644-1170/
 (XOMA) CO: XOMA Corp. ST: California IN: MTC SU: ERN


ML-TM -- SF006 -- 7799 11/05/92 14:25 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 5, 1992
Words:424
Previous Article:DON D. RUTTER NAMED VICE PRESIDENT AND GENERAL MANAGER OF BURNS AEROSPACE CORPORATION AIRCRAFT SEAT FACILITY
Next Article:ST. JOHNSBURY TRUCKING COMPANY PARENT ANNOUNCES RECAPITALIZATION PLAN: PLAN REDUCES DEBT SERVICE, PROVIDES ADDITIONAL WORKING CAPITAL
Topics:


Related Articles
XOMA REPORTS 1992 FIRST QUARTER FINANCIAL RESULTS
XOMA REPORTS 1992 SECOND QUARTER FINANCIAL RESULTS
XOMA ANNOUNCES YEAR-END FINANCIAL RESULTS
XOMA ANNOUNCES U.S. PATENT ON BPI PRODUCTION
MENDELL RESIGNS, CASTELLO ASSUMES CHAIRMAN ROLE AT XOMA
XOMA REPORTS 1993 FIRST QUARTER FINANCIAL RESULTS
XOMA'S NEUPREX(TM) PRODUCT NEUTRALIZES ENDOTOXIN IN HUMANS
PETER DAVIS JOINS XOMA AS CHIEF FINANCIAL OFFICER
MorphoSys Announces Share Issuance for XOMA License.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters